Publication | Closed Access
Diagnostic imaging of human neuroblastoma with radiolabeled antibody.
59
Citations
0
References
1986
Year
Human NeuroblastomaPathologyRadioactivity LevelsMab 3F8GliomaOncologyTheranosticsRadiopharmaceutical TherapyTherapeutic ImagingRadiation OncologyNuclear MedicineMolecular ImagingCancer ResearchRadiation Medicine ImagingRadiologyMonoclonal AntibodyHealth SciencesMedical ImagingHistopathologyRadiologic ImagingMri-guided Radiation TherapyDiagnostic NeuroradiologyTumor MicroenvironmentMedicine
In a previous study, the authors showed that iodine-131 labeled monoclonal antibody (Mab 3F8) could be used to image human neuroblastoma xenografts in mice with excellent tumor-to-tissue ratios. In this study they report their experience with six patients scanned with radiolabeled 3F8. There was strong accumulation of the labeled antibody in viable tumor, but no significant uptake was noted in normal brain, liver, spleen, or adrenal glands. Tumor-to-nontumor activity ratios varied but were approximately 10:1-20:1. This ratio yields good contrast for visualization. Time-activity curves show that radioactivity levels in normal tissue have a half-time of about 40 hours, whereas tumor tissues show a half-time of about 60 hours. Significant gastric secretion of free iodine demonstrated that the Mab was being deiodinated. Calculated radiation doses indicate that tumors receive at least ten times the dose to other tissues. The results indicate that Mab 3F8 has clinical potential for both imaging and therapy of human neuroblastomas.